Clinical Trials List
2018-01-01 - 2027-12-31
Phase III
Recruiting4
-
Trial Applicant
Merck Sharp & Dohme (I.A.) LLC
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
Co-Principal Investigator
- 陳孟延 Division of Oral and Maxillofacial Surgery
- 張展旗 Division of Otolaryngology
- 劉奕廷 Division of Hematology & Oncology
- Kwang-Yu Chang Division of Hematology & Oncology
- 黃振勳 Division of Oral and Maxillofacial Surgery
- 蔡書維 Division of Otolaryngology
- Shang-Yin Wu Division of Hematology & Oncology
- 黃則達 Division of Oral and Maxillofacial Surgery
- 蔡牧宏 Division of Radiation Therapy
- 吳沅樺 Division of Radiation Therapy
- 陳畊仲 Division of Oral and Maxillofacial Surgery
- 歐俊巖 Division of Otolaryngology
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 王成平 Division of Otolaryngology
- 陳俊男 Division of Otolaryngology
- 章浩宏 Division of General Dentistry
- 廖斌志 Division of Hematology & Oncology
- 柯政郁 Division of Otolaryngology
- HSIN-MING CHEN Division of General Dentistry
- 陳贈成 Division of Otolaryngology
- Tsung-Lin Yang Division of Otolaryngology
- 李正喆 Division of General Dentistry
- Pei-Jen Lou Division of Otolaryngology
- YA-FANG CHEN Division of Radiology
- HUAI-CHENG HUANG Division of Hematology & Oncology
- 王駿瑋 Division of Radiation Therapy
- Hsiang-Fong Kao Division of Hematology & Oncology
- 陳婉瑜 Division of Radiation Therapy
- 黃彥霖 Division of Others
- 鄭世榮 Division of General Dentistry
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
30 participants
-
Global
714 participants
